Compare Sun Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GSK PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GSK PHARMA SUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 20.3 232.4 8.7% View Chart
P/BV x 2.2 10.3 21.0% View Chart
Dividend Yield % 0.7 1.5 48.1%  

Financials

 SUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
GSK PHARMA
Mar-19
SUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs6793,595 18.9%   
Low Rs3751,253 30.0%   
Sales per share (Unadj.) Rs121.1184.7 65.6%  
Earnings per share (Unadj.) Rs13.426.3 50.9%  
Cash flow per share (Unadj.) Rs20.729.2 70.9%  
Dividends per share (Unadj.) Rs2.7520.00 13.8%  
Dividend yield (eoy) %0.50.8 63.2%  
Book value per share (Unadj.) Rs172.6126.3 136.6%  
Shares outstanding (eoy) m2,399.26169.40 1,416.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.413.1 33.1%   
Avg P/E ratio x39.492.2 42.7%  
P/CF ratio (eoy) x25.583.1 30.7%  
Price / Book Value ratio x3.119.2 15.9%  
Dividend payout %20.676.1 27.0%   
Avg Mkt Cap Rs m1,264,650410,626 308.0%   
No. of employees `00017.55.0 352.8%   
Total wages/salary Rs m59,6715,372 1,110.8%   
Avg. sales/employee Rs Th16,608.16,306.7 263.3%   
Avg. wages/employee Rs Th3,409.61,083.1 314.8%   
Avg. net profit/employee Rs Th1,833.8898.0 204.2%   
INCOME DATA
Net Sales Rs m290,65931,281 929.2%  
Other income Rs m10,2551,023 1,002.3%   
Total revenues Rs m300,91432,304 931.5%   
Gross profit Rs m63,0766,009 1,049.7%  
Depreciation Rs m17,533486 3,607.5%   
Interest Rs m5,5536 92,541.7%   
Profit before tax Rs m50,2466,540 768.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144287 -4,231.3%   
Tax Rs m6,0092,373 253.2%   
Profit after tax Rs m32,0934,454 720.5%  
Gross profit margin %21.719.2 113.0%  
Effective tax rate %12.036.3 33.0%   
Net profit margin %11.014.2 77.5%  
BALANCE SHEET DATA
Current assets Rs m310,69220,061 1,548.7%   
Current liabilities Rs m173,39614,543 1,192.3%   
Net working cap to sales %47.217.6 267.8%  
Current ratio x1.81.4 129.9%  
Inventory Days Days9957 174.5%  
Debtors Days Days11214 793.5%  
Net fixed assets Rs m232,47714,343 1,620.9%   
Share capital Rs m2,3991,694 141.6%   
"Free" reserves Rs m411,69119,704 2,089.4%   
Net worth Rs m414,09121,398 1,935.2%   
Long term debt Rs m15,2262 761,305.0%   
Total assets Rs m646,93839,113 1,654.0%  
Interest coverage x10.01,091.0 0.9%   
Debt to equity ratio x00 39,340.7%  
Sales to assets ratio x0.40.8 56.2%   
Return on assets %5.811.4 51.0%  
Return on equity %7.820.8 37.2%  
Return on capital %10.231.9 31.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,025534 12,364.3%   
Fx outflow Rs m38,6107,091 544.5%   
Net fx Rs m27,415-6,557 -418.1%   
CASH FLOW
From Operations Rs m21,9653,994 550.0%  
From Investments Rs m-6,813-1,433 475.3%  
From Financial Activity Rs m-27,305-3,584 761.9%  
Net Cashflow Rs m-8,442-1,023 825.0%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.1 10.2 50.3%  
FIIs % 23.0 23.8 96.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 15.4 53.9%  
Shareholders   133,026 102,036 130.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  ABBOTT INDIA  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

How to Trade this Market Crash(Podcast)

India's #1 trader, Vijay Bhambwani, decodes the crash...and reveals hidden opportunities one could profit from.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Feb 26, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade.

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

This is What You Must Know as an Options Trader Today(Fast Profits Daily)

Feb 27, 2020

How you can stay on top of the challenges as an options trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 28, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS